Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 5,000 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.30 during midday trading on Wednesday, reaching $93.78. The company had a trading volume of 2,331,021 shares, compared to its average volume of 3,400,369. The company has a market capitalization of $56.51 billion, a P/E ratio of 40.29, a P/E/G ratio of 3.36 and a beta of 1.11. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm’s fifty day simple moving average is $88.51 and its 200-day simple moving average is $86.16. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on EW shares. The Goldman Sachs Group started coverage on Edwards Lifesciences in a report on Thursday, May 30th. They set a “buy” rating and a $107.00 target price for the company. Stifel Nicolaus upped their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday, April 26th. Citigroup raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $98.00 to $105.00 in a research report on Wednesday, May 22nd. Mizuho upped their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Finally, OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $95.18.

Institutional Trading of Edwards Lifesciences

Hedge funds have recently bought and sold shares of the business. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $28,000. Riverview Trust Co purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth $34,000. DSM Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth $28,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth $34,000. Finally, Rise Advisors LLC raised its stake in Edwards Lifesciences by 125.0% during the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock worth $46,000 after acquiring an additional 265 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.